1. Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature
- Author
-
E E Zvonkov, N G Gabeeva, M M Chukavina, D A Koroleva, T N Obukhova, and Alla M. Kovrigina
- Subjects
Male ,Oncology ,History ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,lenalidomide ,lcsh:Medicine ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Asparaginase ,Humans ,B cell ,Neoplasm Staging ,Lenalidomide ,Chemotherapy ,business.industry ,Daunorubicin ,lcsh:R ,Hematopoietic Stem Cell Transplantation ,non-gcb- dlbcl ,Germinal center ,gcb- dlbcl ,General Medicine ,Middle Aged ,Germinal Center ,medicine.disease ,Progression-Free Survival ,Lymphoma ,Gene expression profiling ,medicine.anatomical_structure ,Vincristine ,Prednisone ,Immunohistochemistry ,Lymphoma, Large B-Cell, Diffuse ,auto-hematopoietic stem cell transplantation ,dlbcl ,Family Practice ,business ,IRF4 ,medicine.drug - Abstract
Diffuse large B-cell lymphoma is categorized by gene expression profiling into germinal center (GCB) and activated B-cell (ABC) subtype, also referred to as non-germinal center B-cell (non-GCB) by immunohistochemistry. ABC DLBCL is characterized by NF-κB pathway activation and high expression of IRF4/MUM1, a key transcription factor in B cell differentiation. Patients with ABC DLBCL have a significantly worse outcome when treated with standard chemotherapy (R-CHOP). Lenalidomide have shown activity in the ABC-DLBCL in combination with R-CHOP. But about 40% of patients remain resistant. We present the experience of treatment of a patient with generalized non-GCB-DLBCL using the intensive protocol R-mNHL-BFM-90 with lenalidomide.
- Published
- 2018
- Full Text
- View/download PDF